GDNF and Parkinson disease: Therefore, the search for new therapies in Parkinson’s disease should now focus on slowing degenerative processes in the GABAergic striatum and restoring fully functional GDNF synthesis—the main chemoattractant for dopaminergic synaptogenesis and neurogenesis and migration of GABA interneurons [138].